GWS
MDGL icon

Glassman Wealth Services’s Madrigal Pharmaceuticals MDGL Stock Holding History

Glassman Wealth Services’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$231 – 2032
2023
Q2 		$231 Buy
+1
New +$271 ﹤0.01% 1782

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Glassman Wealth Services's MDGL Position: Q3 2023 in Review

Glassman Wealth Services sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 1 share — an estimated $231 sold.

Glassman Wealth Services first reported a position in MDGL in Q2 2023 and held it in 1 quarter. The position peaked at $231 in Q2 2023. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • Glassman Wealth Services reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Glassman Wealth Services sold 1 Madrigal Pharmaceuticals share in Q3 2023, an estimated $231.
  • Glassman Wealth Services first reported a position in Madrigal Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Glassman Wealth Services's Madrigal Pharmaceuticals position peaked at $231 in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Glassman Wealth Services's 13F filing for Q3 2023, filed 14 Nov 2023.